23 completed, 9 terminated, 7 unknown, 6 active not recruiting. 54 Phase 2, 7 Phase 1, 7 Phase 3.
Follow Lomustine: new trials by email Literature Review of Lomustine trials Research Report on Lomustine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment Lomustine, Anlotinib - SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Yayi He | 46 | 2026-06-01 | 2026-06-08 |
| A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma L19TNF, L19TNF and TMZ, L19TNF and CCNU - Glioma | Phase 2 | Not yet recruiting | Philogen S.p.A. | 52 | 2026-01-30 | 2025-08-13 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-11-03 |
| Lerapolturev (PVSRIPO) in GBM Lerapolturev, Lomustine Pill - Recurrent Supratentorial Glioblastoma | Phase 2 | Recruiting | Darell Bigner | 92 | 2024-07-15 | 2026-07-20 |
| A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence L19TNF, Lomustine - Glioblastoma | Phase 2 | Active not recruiting | Philogen S.p.A. | 90 | 2024-05-22 | 2026-04-21 |
| Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma Sonidegib, Cisplatin, Lomustine - Medulloblastoma | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 20 | 2022-11-11 | 2025-10-23 |
| Phase II Trial of Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-meth Glioblastoma Lomustine, Romiplostim - First Progression of MGMT Promoter-methylated Glioblastoma | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2022-09-13 | 2023-05-24 | |
| Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma Lomustine, Imipramine Hydrochloride - Glioblastoma | Phase 2 | Recruiting | The University of Texas Health Science Center at San Antonio | 25 | 2022-05-25 | 2025-08-27 |
| A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Berubicin, Lomustine - Glioblastoma Multiforme, Adult | Phase 2 | Active not recruiting | CNS Pharmaceuticals, Inc. | 252 | 2021-05-18 | 2026-04-15 |
| A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression L19TNF, Lomustine - Glioblastoma | Phase 1 / Phase 2 | Unknown | Philogen S.p.A. | 142 | 2021-02-19 | 2024-04-08 |
| A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Selinexor, Temozolomide (TMZ), Lomustine (CCNU) - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | Karyopharm Therapeutics Inc | 74 | 2020-06-08 | 2024-12-16 |
| Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Indoximod, Partial Radiation, Full-dose Radiation - Glioblastoma, Medulloblastoma | Phase 2 | Active not recruiting | Theodore S. Johnson | 130 | 2019-10-02 | 2026-11-02 |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Temozolomide, Lomustine, Regorafenib - Glioblastoma | Phase 2 / Phase 3 | Recruiting | Global Coalition for Adaptive Research | 2250 | 2019-07-30 | 2026-11-02 |
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
| Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients Chlorogenic acid for Injection, Lomustine - GBM | Phase 2 / Phase 3 | Unknown | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | 200 | 2018-11-27 | 2018-11-29 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme Sunitinib, Lomustine - Glioblastoma Multiforme, Glioblastoma, Adult | Phase 2 / Phase 3 | Unknown | Amsterdam UMC, location VUmc | 100 | 2018-08-31 | 2021-04-19 |
| Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab - High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma | Phase 2 | Completed | Aadi Bioscience, Inc. | 62 | 2018-08-01 | 2023-11-07 |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects VBI-1901, Carmustine, Lomustine - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | VBI Vaccines Inc. | 70 | 2017-12-06 | 2026-05-08 |
| Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Cisplatin, Cyclophosphamide, Laboratory Biomarker Analysis - Medulloblastoma | Phase 2 | Active not recruiting | Children's Oncology Group | 45 | 2017-11-17 | 2026-07-16 |
Showing 20 of 54. Sign in to see all of them.
Glioblastoma (28) · Brain Neoplasms (11) · Central Nervous System Neoplasms (7) · Astrocytoma (6) · Lymphoma (6) · Medulloblastoma (6) · Recurrence (6) · Glioma (5) · Neoplasms (5) · Lung Neoplasms (2) · Lymphoma, AIDS-Related (2) · Lymphoma, Non-Hodgkin (2) · Oligodendroglioma (2) · Sarcoma (2) · Adenocarcinoma of Lung (1)
Case Comprehensive Cancer Center (4) · M.D. Anderson Cancer Center (3) · Philogen S.p.A. (3) · Children's Cancer and Leukaemia Group (2) · Children's Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Memorial Sloan Kettering Cancer Center (2) · AIDS Malignancy Consortium (1) · Aadi Bioscience, Inc. (1) · AbbVie (1) · Actuate Therapeutics Inc. (1) · Advenchen Pharmaceuticals, LLC. (1) · Alliance for Clinical Trials in Oncology (1) · Amsterdam UMC, location VUmc (1) · Bart Neyns (1)
United States (32) · France (10) · Canada (9) · Germany (9) · Italy (9) · Spain (9) · Switzerland (8) · Netherlands (7) · Australia (5) · Austria (5) · Belgium (5) · United Kingdom (5) · Ireland (4) · Poland (3) · Portugal (3)
Scot C. Remick, MD (4) · Barry Pizer, MD (2) · David Ellison, MD (2) · Frank Saran, MD (2) · Jan C. Buckner, MD (2) · Roger Taylor, MD (2) · Anatolij D Namgaladze, Master (1) · Andrew B Lassman, MD (1) · Asgeir S Jakola, MD, PhD (1) · Barbara J O'Brien (1) · Carlos K Matsuoka, MD (1) · Charles Conrad, MD (1)
PMID 40967259, PMID 12525516, PMID 18976072, PMID 20725730, PMID 22851558, PMID 24327518, PMID 24419119, PMID 24947255, PMID 26902851, PMID 27050206, PMID 27252174, PMID 27424289, PMID 27843136, PMID 28039367, PMID 28053024, PMID 28672195, PMID 29077941, PMID 29383130, PMID 29846250, PMID 29982805, PMID 30266892, PMID 30405781, PMID 30522967, PMID 30647912, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31747009, PMID 31795071, PMID 31831767, PMID 31882719, PMID 31894292, PMID 31903699, PMID 32706640, PMID 33119048, PMID 33601293, PMID 34388515, PMID 34540703, PMID 35815408, PMID 37000452, PMID 37072349, PMID 37224228, PMID 38773224, PMID 40073837, PMID 41980234, PMID 41981308
P30CA043703 (4), 2014 (2), 2009 (1), P30CA006973 (1), P30CA008748 (1), P30CA016672 (1), R01CA229646 (1), U01CA121947 (1), U10CA098543 (1), U10CA180821 (1), U10CA180886 (1)